Fourth-quarter earnings and guidance for 2017 were not what the doctor ordered.
News & Analysis: Aralez Pharmaceuticals
The biotech gained FDA approval for its aspirin-containing medication, Yosprala.
Investors pile in as the biotech awaits a decision from the FDA.
Investors continue to grow bullish on the prospects of its pending acquisition of Tribute Pharmaceuticals, but this Fool thinks there are reasons to be cautious.
POZEN shares ascend to the heavens after it announces an acquisition. Normally the acquired company is the one that soars, but there's a big catch to this acquisition that POZEN shareholders are going to like.
Three Motley Fool analysts tell investors which three FDA decisions they'll be watching closely in December.
Why this move up makes sense.
POZEN shares hit the sales rack after receiving unwelcome news from the Food and Drug Administration. Find out why this may not be as bad as it appears on the surface.
POZEN, Lionbridge Technologies, and Westmoreland Coal are this week's must-watch stocks.
Horizon's (HZNP) purchase of AstraZeneca's (AZN) rights to Pozen's VImovo and Sanofi's bet on Pozen's cardiovascular drug have big implications for Pozen's future.